Identifying abundant immunotherapy and other targets in solid tumors integrating RNA-seq and mass spectrometry proteomics data sets

Wei Zhao, Matthew Fitzgibbon, Lindsay Bergan, Nigel Clegg, David Crispin, Gordon Mills, Martin Mcintosh

Research output: Contribution to journalReview article

Abstract

RNA-seq and mass-spectrometry proteomics combined with growing data repositories have greatly increased the capacity to identify candidate proteins or protein sequence variants that share properties of ideal therapy targets, which include being abundant in cancer cells, absent or rare in adult organs (especially vital organs), and shared by many patient tumors. RNA-seq and fixed content arrays can identify genes that are overexpressed or misexpressed in cancer. RNA-seq is uniquely suited to identifying cancer-specific sequence variants. We review factors relevant for determining whether products of genes that are abundant or differentially abundant in RNA-seq are concordant or discordant with proteins that are identified as abundant or differentially abundant in mass-spectrometry proteomics assays.

Original languageEnglish (US)
Pages (from-to)108-114
Number of pages7
JournalCancer Journal (United States)
Volume23
Issue number2
DOIs
StatePublished - Jan 1 2017
Externally publishedYes

Fingerprint

Proteomics
Immunotherapy
Mass Spectrometry
RNA
Neoplasms
Proteins
Genes
Datasets
Therapeutics

Keywords

  • Candidate proteins
  • Protein sequence variants
  • RNA-seq

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Identifying abundant immunotherapy and other targets in solid tumors integrating RNA-seq and mass spectrometry proteomics data sets. / Zhao, Wei; Fitzgibbon, Matthew; Bergan, Lindsay; Clegg, Nigel; Crispin, David; Mills, Gordon; Mcintosh, Martin.

In: Cancer Journal (United States), Vol. 23, No. 2, 01.01.2017, p. 108-114.

Research output: Contribution to journalReview article

Zhao, Wei ; Fitzgibbon, Matthew ; Bergan, Lindsay ; Clegg, Nigel ; Crispin, David ; Mills, Gordon ; Mcintosh, Martin. / Identifying abundant immunotherapy and other targets in solid tumors integrating RNA-seq and mass spectrometry proteomics data sets. In: Cancer Journal (United States). 2017 ; Vol. 23, No. 2. pp. 108-114.
@article{b313231cb10d46afb323243607116e7f,
title = "Identifying abundant immunotherapy and other targets in solid tumors integrating RNA-seq and mass spectrometry proteomics data sets",
abstract = "RNA-seq and mass-spectrometry proteomics combined with growing data repositories have greatly increased the capacity to identify candidate proteins or protein sequence variants that share properties of ideal therapy targets, which include being abundant in cancer cells, absent or rare in adult organs (especially vital organs), and shared by many patient tumors. RNA-seq and fixed content arrays can identify genes that are overexpressed or misexpressed in cancer. RNA-seq is uniquely suited to identifying cancer-specific sequence variants. We review factors relevant for determining whether products of genes that are abundant or differentially abundant in RNA-seq are concordant or discordant with proteins that are identified as abundant or differentially abundant in mass-spectrometry proteomics assays.",
keywords = "Candidate proteins, Protein sequence variants, RNA-seq",
author = "Wei Zhao and Matthew Fitzgibbon and Lindsay Bergan and Nigel Clegg and David Crispin and Gordon Mills and Martin Mcintosh",
year = "2017",
month = "1",
day = "1",
doi = "10.1097/PPO.0000000000000258",
language = "English (US)",
volume = "23",
pages = "108--114",
journal = "Cancer journal (Sudbury, Mass.)",
issn = "1528-9117",
publisher = "Lippincott Williams and Wilkins Ltd.",
number = "2",

}

TY - JOUR

T1 - Identifying abundant immunotherapy and other targets in solid tumors integrating RNA-seq and mass spectrometry proteomics data sets

AU - Zhao, Wei

AU - Fitzgibbon, Matthew

AU - Bergan, Lindsay

AU - Clegg, Nigel

AU - Crispin, David

AU - Mills, Gordon

AU - Mcintosh, Martin

PY - 2017/1/1

Y1 - 2017/1/1

N2 - RNA-seq and mass-spectrometry proteomics combined with growing data repositories have greatly increased the capacity to identify candidate proteins or protein sequence variants that share properties of ideal therapy targets, which include being abundant in cancer cells, absent or rare in adult organs (especially vital organs), and shared by many patient tumors. RNA-seq and fixed content arrays can identify genes that are overexpressed or misexpressed in cancer. RNA-seq is uniquely suited to identifying cancer-specific sequence variants. We review factors relevant for determining whether products of genes that are abundant or differentially abundant in RNA-seq are concordant or discordant with proteins that are identified as abundant or differentially abundant in mass-spectrometry proteomics assays.

AB - RNA-seq and mass-spectrometry proteomics combined with growing data repositories have greatly increased the capacity to identify candidate proteins or protein sequence variants that share properties of ideal therapy targets, which include being abundant in cancer cells, absent or rare in adult organs (especially vital organs), and shared by many patient tumors. RNA-seq and fixed content arrays can identify genes that are overexpressed or misexpressed in cancer. RNA-seq is uniquely suited to identifying cancer-specific sequence variants. We review factors relevant for determining whether products of genes that are abundant or differentially abundant in RNA-seq are concordant or discordant with proteins that are identified as abundant or differentially abundant in mass-spectrometry proteomics assays.

KW - Candidate proteins

KW - Protein sequence variants

KW - RNA-seq

UR - http://www.scopus.com/inward/record.url?scp=85018984406&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018984406&partnerID=8YFLogxK

U2 - 10.1097/PPO.0000000000000258

DO - 10.1097/PPO.0000000000000258

M3 - Review article

C2 - 28410298

AN - SCOPUS:85018984406

VL - 23

SP - 108

EP - 114

JO - Cancer journal (Sudbury, Mass.)

JF - Cancer journal (Sudbury, Mass.)

SN - 1528-9117

IS - 2

ER -